Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-LEAP long-acting erythropoietin in preterm infants with anemia of prematurity
jRCT2051260141Phase 3Not yet recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of methoxy polyethylene glycol-epoetin beta in anemia of prematurity (AOP) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Lowest hemoglobin concentration during observation. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of prematurity (AOP)
Beyond the preview
Go deeper on jRCT2051260141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260141.